Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Changes in laboratory and DXA parameters in multiple myeloma patients treated with romosozumab. | M0 | M6 | M12 | p-value: 25 (OH) vitamin D (ng/mL), median (IQR) | 27.5 (26.0-45.9) | 43 (33.0-44.6) | 45.4 (35.9-56.1) | .090
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study
Observational study · JBMR Plus · 2025
Original publication title
Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study
© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Bone damage occurs early in the progression of plasma cell disorders. Romosozumab (ROMO), a sclerostin inhibitor with both anabolic and antiresorptive effects, may provide therapeutic benefit for this fracture-prone population. We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO. BMD was assessed at baseline, 6, and 12 mo with DXA and HR-pQCT. Additionally, bone turnover markers (BTMs) and several MM markers were also monitored. Eight female patients with MM without evidence of CRAB completed 12 mo of ROMO.
A significant BMD increase was observed at the LS (+5.8%, p = .048), FN (+4.2%, p = .020), and TH (+3.3%, p = .002). Procollagen I intact N-terminal peptide rose sharply at month 3 (+117.8%) and returned to baseline by month 12 (p = .006). C-terminal telopeptide of type I collagen decreased progressively, showing a trend toward significance (−53.6%, p = .060). Alkaline phosphatase and bone alkaline phosphatase significantly declined by month 12 (p = .020 and p = .022).
No significant changes occurred in immunoglobulins, M-protein, or light chains. β2-microglobulin decreased at month 12 (from 2.35 to 2.1 mg/L, p = .042), but the overall trend was not significant (p = .092). Failure load increased at month 6 (p = .033), while the other HR-pQCT parameters remained stable throughout the study. In this exploratory study of postmenopausal women with MM and osteoporosis, ROMO significantly improved BMD and modulated BTMs, without any evidence of disease progression over the 12-mo period.
These findings support ROMO as a potential bone-targeted therapy in patients with osteoporosis and MM.
Authors’ abstract
Abstract
Bone damage occurs early in the progression of plasma cell disorders. Romosozumab (ROMO), a sclerostin inhibitor with both anabolic and antiresorptive effects, may provide therapeutic benefit for this fracture-prone population. We conducted a 12-mo prospective observational study on postmenopausal women with osteoporosis and multiple myeloma (MM) treated with monthly ROMO. BMD was assessed at baseline, 6, and 12 mo with DXA and HR-pQCT. Additionally, bone turnover markers (BTMs) and several MM markers were also monitored. Eight female patients with MM without evidence of CRAB completed 12 mo of ROMO.
A significant BMD increase was observed at the LS (+5.8%, p = .048), FN (+4.2%, p = .020), and TH (+3.3%, p = .002). Procollagen I intact N-terminal peptide rose sharply at month 3 (+117.8%) and returned to baseline by month 12 (p = .006). C-terminal telopeptide of type I collagen decreased progressively, showing a trend toward significance (−53.6%, p = .060). Alkaline phosphatase and bone alkaline phosphatase significantly declined by month 12 (p = .020 and p = .022).
No significant changes occurred in immunoglobulins, M-protein, or light chains. β2-microglobulin decreased at month 12 (from 2.35 to 2.1 mg/L, p = .042), but the overall trend was not significant (p = .092). Failure load increased at month 6 (p = .033), while the other HR-pQCT parameters remained stable throughout the study. In this exploratory study of postmenopausal women with MM and osteoporosis, ROMO significantly improved BMD and modulated BTMs, without any evidence of disease progression over the 12-mo period.
These findings support ROMO as a potential bone-targeted therapy in patients with osteoporosis and MM.
Publication and source details
Original title: Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study
Mariana Diz Lopes; Francesco Pollastri; Francesca Mastropaolo; Rosanna Somma; Mattia Tugnolli; Emma Pasetto; Camilla Benini; Valeria Messina; Davide Gatti; Ombretta Viapiana; Maurizio Rossini; Elena Marchetti; Martina Tinelli; Giovanni Adami
JBMR Plus · 2025
Corresponding author: Giovanni Adami, Rheumatology Section, Department of Medicine, University of Verona, Pz Scuro 10, 37134 Verona, Italy (giovanni.adami@univr.it).© The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:11:15.115766+00:00
DOI: 10.1093/jbmrpl/ziaf144 · PMC12452266